Plain-English translation of NCT06799520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage clinical trial is testing a new medication called , given as a subcutaneous injection (under the skin), in people who have autoimmune diseases including systemic lupus erythematosus, alopecia areata, or immune-mediated focal segmental glomerulosclerosis. The study will measure how safe the medication is, how well patients tolerate it, and how the body responds to it over about 9 to 12 months.
Autoimmune diseases occur when the body's immune system mistakenly attacks its own cells and tissues, causing inflammation and damage. This medication is designed to help calm the immune system, and researchers want to understand whether this new treatment is safe enough and works well enough in people to potentially help them manage their condition.
You would receive subcutaneous injections of the medication once weekly from Week 1 through Week 21, while continuing your regular autoimmune disease treatments. Throughout the 9 to 12 month study period, you would have several clinic visits for blood tests, urine tests, and physical exams so the researchers can monitor your health, measure how much of the medication is in your body, and check for any side effects.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
Bulgaria
Moldova
Romania
Spain